세계의 장기 칩 시장 규모는 2022년에 1억 2,000만 달러로 평가되며, 2023년 1억 6,224만 달러에서 2031년에는 18억 1,122만 달러로 성장하며, 예측 기간(2024-2031년)의 CAGR은 35.2%로 성장할 전망입니다.
장기 칩 시장은 기술의 진보나 제약, 바이오테크놀러지, 학술 분야에서의 채택 확대에 의해 급성장을 달성하고 있으며, 동물실험 대체 수요 및 조기 약물 반응 검출에 대한 필요성에 힘입어 빠르게 성장하고 있습니다. 이 마이크로플루이딕스 세포배양 장비는 장기 기능 시뮬레이션, 질병 모델링, 약물 설계, 독성 테스트 등 다양한 용도로 활용될 수 있습니다. 특히 최근 ISS 국립연구소에 보내진 에뮬레이트의 브레인 칩과 같은 노력은 이 기술의 혁신적 잠재력을 강조하고 있으며, COVID-19 이후의 상황은 이해관계자들이 의료 환경내 장기 적용을 확대하고자 하는 수요를 더욱 강화시키고 있습니다. 더욱 강화하고 있습니다. 그 결과, 세계 장기 칩 시장은 예측 기간 중 연평균 30.76%의 괄목할 만한 성장세를 보이며 의약품 개발 및 연구 방법을 재구성할 것으로 예측됩니다.
Global Organ On Chip Market size was valued at USD 120.0 million in 2022 and is poised to grow from USD 162.24 million in 2023 to USD 1811.22 million by 2031, growing at a CAGR of 35.2% during the forecast period (2024-2031).
The organ-on-a-chip market is witnessing rapid growth due to technological advancements and increased adoption across pharmaceutical, biotechnology, and academic sectors, driven by the demand for alternatives to animal testing and the need for early drug reaction detection. This microfluidic cell culture device simulates organ functions and offers diverse applications in disease modeling, drug design, and toxicity testing. Notably, recent initiatives, such as Emulate, Inc.'s Brain Chip sent to the ISS National Lab, highlight the technology's innovative potential. The post-COVID-19 landscape has further intensified this demand, as stakeholders aim to expand organ applications within healthcare settings. Consequently, the global organ-on-a-chip market is projected to grow at a remarkable CAGR of 30.76% during the forecast period, reshaping drug development and research methodologies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Organ On Chip market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Organ On Chip Market Segmental Analysis
Global Organ On Chip Market is segmented by organ type, model type, product, purpose, application, end user and region. Based on organ type, the market is segmented into liver, kidney, intestine, lung, heart and other organs. Based on model type, the market is segmented into organ-based models and disease-based models. Based on product, the market is segmented into services and products. Based on purpose, the market is segmented into therapeutics and research. Based on application, the market is segmented into toxicology research, drug discovery, physiological model development, tissue regeneration & regenerative medicine and stem cell research. Based on end user, the market is segmented into pharmaceutical and biotechnology companies, cosmetics industry, academic & research institutes and other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Organ On Chip Market
The Global Organ-On-Chip market is significantly driven by the growing demand for animal-free testing solutions. As awareness regarding ethical considerations and animal welfare continues to increase among consumers globally, there is a strong advocacy for alternatives to traditional testing methods. Organ-on-chip technologies are emerging as vital tools in drug discovery and toxicity assessments, offering reliable and humane options for researchers. This shift towards innovative, non-animal testing platforms is likely to provide substantial momentum to the market, as organizations seek to align with consumer preferences while enhancing the efficiency and accuracy of their scientific evaluations.
Restraints in the Global Organ On Chip Market
The Global Organ-On-Chip market faces significant restraints due to various ethical and societal challenges. Chief among these concerns are the ethical implications related to the use of human cells, tissues, and organs in research, which raise questions about informed consent, privacy, and the ethical sourcing of biological materials. It is crucial to navigate these ethical, legal, and societal issues responsibly, particularly regarding animal welfare. Addressing these challenges is vital for fostering sustainable growth and development in the market, as stakeholders must ensure that their practices align with ethical standards while promoting innovation and accessibility in organ-on-chip technology.
Market Trends of the Global Organ On Chip Market
The Global Organ-On-Chip market is witnessing a notable trend towards enhancing the accuracy of drug predictions, driven by escalating R&D costs and waning effectiveness in pharmaceuticals. As drug development faces critical challenges, companies are increasingly adopting organ-on-chip technologies to simulate human organ responses accurately, thereby reducing dependence on traditional animal testing. This innovative approach not only streamlines the drug development process but also improves safety assessments and efficacy predictions. The growing demand for personalized medicine and regulatory pressure for better predictive models further propels market growth, positioning organ-on-chip solutions as a pivotal tool for the future of pharmaceutical research and development.